News By Tag
News By Location
'Report predicts world antibacterial drugs market will reach $43.8bn in 2016' says Visiongain report
A new report by visiongain, a London-based business information company, predicts that world revenues for antibacterial drugs will reach $43.81bn in 2016.
Visiongain forecasts that cephalosporins will remain the largest sector of the market throughout the forecast period, with revenues growing to $11.67bn by 2016. The fastest growing class of antibacterial drug will be the carbapenems, revenues for which will grow with a CAGR of 3% between 2010 and 2022. Increased uptake in place of other drug classes will drive this growth, as will the class's low susceptibility to bacterial resistance.
The visiongain pharmaceutical industry analyst, said: "The market will rely on strong uptake of new drugs, such as Ortho-McNeil/
This study forecasts the future of the leading five classes of antibacterial drug, as well as the top 20 individual drugs, showing revenue forecasts to 2022. In 2010, only two blockbusters existed in the antibacterial drugs market - Levaquin and Zyvox - and both products are expected to have revenues below $1bn by 2017.
Leading national markets are also analysed and discussed in the report, with market forecasts provided. In 2010, China was the world's second largest market for antibacterial drugs. Antibiotics apparently accounted for 70% of all prescriptions there in 2008. That market will continue to grow more rapidly than those of other leading countries this decade, despite rules introduced in 2011 to limit antibiotic drug prescription.
Urgent medical needs exist in the antibacterial drugs industry and market, as a result of bacterial resistance to antibiotics. Nosocomial infections are a major burden on healthcare budgets in developed and developing countries. With a weak R&D pipeline - particularly against Gram-negative infections - expansion of the antibacterial drugs market will slow over the coming 10 years. Antibacterial Drugs: World Market Prospects 2012-2022 adds to visiongain's range of analytical research covering important therapeutic areas of the pharmaceutical industry.
To view sample pages please visit http://www.visiongain.com/
Please contact Sara Peerun for an exec summary:
Tel: +44 020 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@
# # #
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.